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Introduction
Cystic fibrosis (CF) is a multi-system genetic condition but the 
two main affected organs are lungs (resulting in recurrent infections 
and respiratory failure) and gastrointestinal tract (resulting in fat 
malabsorption and poor growth)1. Median survival has improved 
to 45 years, in part because of improvement in care quality2. An 
important quality improvement initiative is benchmarking, which 
involves identifying high-performing centres and the practices 
associated with outstanding performance3–5. Since forced 
expiratory volume in one second (FEV
1
) is an important CF 
prognostic marker6–9, it is often used as an outcome measure for 
benchmarking3–5,10.
Different statistical methods of analysing FEV
1
 data can yield 
different results11, but there is scant attention paid to the methods 
of processing FEV
1
 data. We previously reported a statistically 
significant reduction in year-to-year %FEV
1
 fall for our CF 
centre from 2013–201612. We now set out to understand the 
impact of using different FEV
1
 data processing methods on our 
CF centre’s outcome.
Methods
This is a single-centre retrospective analysis of routinely 
collected clinical data from 2013–2016. Regulatory approval for 
the analysis was obtained from NHS Health Research Authority 
(IRAS number 210313). All adults with CF diagnosed accord-
ing to the UK CF Trust criteria aged ≥16 years were included, 
except those with lung transplantation or on ivacaftor. These 
treatments have transformative effects on %FEV
1
13–15, thus 
may affect the interpretation of year-to-year variation in %FEV
1
.
Demographic data (age, gender, genotype, pancreatic status, CF 
related diabetes, Pseudomonas aeruginosa status), body mass 
index (BMI) and FEV
1
 data were collected by two investiga-
tors (HZH and RC / HZH and MEG) independently reviewing 
paper notes and electronic records. Where data from the two 
investigators differ, the original data from paper notes or electronic 
records were reviewed to by both investigators to ensure the 
accuracy of abstracted data. This process ensures the accuracy 
of abstracted data and helps avoid potential bias from inaccurate 
or inconsistent data collection16. FEV
1
 data were processed with 
three different methods prior to analysis. First, %FEV
1
 readings 
(calculated with Knudson equation17 and available in whole 
numbers) were directly extracted from spirometer machines. 
Second, FEV
1
 volumes (in litres, to two decimal places) were 
extracted and clean height data were used to calculate %FEV
1
 (as 
whole numbers) with Knudson equation17. Third, FEV
1
 volumes 
(in litres, to two decimal places) were extracted and clean 
height data were used to calculate %FEV
1
 with GLI equation18 
using an Excel Macro (Microsoft Excel 2013).
Best %FEV
1
, i.e. the highest %FEV
1
 reading in a calendar year 
for each study subject was used for analysis since it is most reflec-





was calculated by subtracting best %FEV
1
 at Year 1 from Year 2 
(i.e. negative values indicate fall in %FEV
1
 and positive values 
indicate increase in %FEV
1
). In addition to calculating year-to-
year %FEV
1
 change using three different FEV
1
 data processing 
methods, %FEV
1
 change calculated with GLI equation was 
also adjusted for baseline %FEV
1
 using reference values from 
Epidemiologic Study of CF (ESCF)20. The ESCF study found 
median %FEV
1
 change of –3%/year, –2%/year and –0.5%/year 
for baseline %FEV1 ≥100%, 40–99.9% and <40% respectively20. 
Adjusted %FEV
1
 change was calculated by subtracting median 
ESCF %FEV
1
 change from actual %FEV
1
 change. Thus, an 
adjusted %FEV
1
 change >0 meant the subject’s year-to-year 
change in %FEV1 was less than expected (indicating better health 
outcome) whilst an adjusted %FEV
1
 change <0 meant the 
subject’s year-to-year change in %FEV
1
 was more than expected 
(indicating worse health outcome). 
%FEV
1
 change from 2013–2014 to 2015–2016 calculated using 
different FEV
1
 data processing methods were compared using 
Friedman test. Bland-Altman analyses21 were also used to com-
pare year-to-year variation in FEV1 as calculated with Knudson 
equation against year-to-year variation in FEV1 as calculated 
with GLI equation, to understand the impact of using different 
reference equations. Analyses were performed using SPSS v24 
(IBM Corp) and Prism v7 (GraphPad Software). P-value <0.05 
was considered statistically significant.
Results
This analysis included 208 adults, with 147 adults providing data 
for all four years. Overall, the cohort was ageing but 
baseline %FEV
1
 increased from 2014 onwards (see Table 1).
The %FEV
1
 increase was in part due to younger adults with 
higher %FEV
1
 transitioning from paediatric care because 
%FEV
1
 tended to decline from year to year (see Table 2). 
However, different year-to-year change in %FEV
1
 results were 
obtained with different FEV
1
 data processing methods. There was 
statistically significant reduction in year-to-year fall in %FEV1 
using %FEV1 readings as recorded in spirometer machines 
(p=0.016). Cleaning of height data and standardisation of 
%FEV
1
 calculation with Knudson equation17 did not alter the 
magnitude of year-to-year variation in %FEV
1
, but the p-value 
was no longer statistically significant (p=0.062). The use of 
      Amendments from Version 1
As recommended by Prof McKone, we have used Bland-Altman 
analyses to compare different reference equations (Knudson vs 
GLI).
As recommended by Prof Burgel, we have:
1.   Performed a sensitivity analysis for the results in Table 2 
using only adults aged 18 years and above - we have also 
done the same for the Bland-Altman analyses that were 
added following suggestion from Prof McKone
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Table 1. Characteristics of study subjects from 2013 to 2016.
2013 2014 2015 2016
Excluded 
     Lung transplantation, n 









Included, n 166 170 185 186
Age in years, median (IQR) 25 (19 – 31) 26 (20 – 32) 27 (20 – 34) 27 (21 – 34)
Female, n (%) 76 (45.8) 80 (47.1) 87 (47.0) 90 (48.4)
Genotype status: ¶ 
     ≥1 unknown mutation(s), n (%) 
     ≥1 class IV-V mutation(s), n (%) 













Pancreatic insufficient, † n (%) 137 (82.5) 135 (79.4) 142 (76.8) 145 (78.0)
CF related diabetes, ‡ n (%) 39 (23.5) 42 (24.7) 42 (22.7) 54 (29.0)
P. aeruginosa status: § 
     No P. aeruginosa, n (%) 
     Intermittent P. aeruginosa, n (%) 













BMI, median (IQR) 22.3 (19.7 – 24.6) 22.7 (20.0 – 25.0) 23.0 (20.3 – 26.0) 23.2 (20.4 – 26.0)
Best %FEV
1
, median (IQR) 78.7 (54.1 – 92.5) 76.6 (54.4 – 89.7) 77.8 (60.4 – 89.0) 78.5 (58.5 – 89.6)
¶ Genotype status as defined by international consensus22. Homozygous class I-III mutations indicate ‘severe genotype’.
† Pancreatic insufficiency was diagnosed by the clinical team on the basis of ≥2 faecal pancreatic elastase levels <200µg/g stool and symptoms 
consistent with maldigestion and malabsorption, in accordance to the UK Cystic Fibrosis (CF) Trust guideline.
‡ CF related diabetes was diagnosed by the clinical team on the basis of oral glucose tolerance test and continuous subcutaneous glucose monitoring 
results, in accordance to the UK CF Trust guideline.
§ Pseudomonas aeruginosa status was determined according to the Leeds criteria23.
Table 2. Discrepancies in year-to-year %FEV
1




Methods of processing FEV1 data:
Change in %FEV1, median (IQR) Friedman 
test 
p-values
2013 to 2014 
(n = 158)
2014 to 2015 
(n = 162)




 (calculated with Knudson equation) extracted from 
spirometer machines used for analysis †
–2.0 (–6.0 to 1.0) –1.0 (–3.3 to 2.0) 0.0 (–3.0 to 2.0) 0.016
(2) FEV
1
 volume (in L) extracted and height data were cleaned, 
then %FEV
1
 calculated using Knudson equation ‡
–2.0 (–5.0 to 1.0) –1.0 (–4.0 to 1.0) 0.0 (–3.8 to 2.0) 0.062
(3) FEV
1
 volume (in L) extracted and height data were cleaned, 
then %FEV
1
 calculated using GLI equation Ԅ –1.1 (–4.6 to 1.5) –0.9 (–3.2 to 1,5) –0.3 (–2.9 to 1.8) 0.135
(4) FEV
1
 volume (in L) extracted and height data were cleaned, 
then %FEV
1
 calculated using GLI equation, then change %FEV
1
 
adjusted for baseline %FEV
1
 using ESCF reference values §
0.7 (–2.4 to 3.6) 1.1 (–1.4 to 3.5) 1.6 (–1.3 to 3.7) 0.210
ESCF - Epidemiologic Study of cystic fibrosis
† The vast majority of the %FEV
1
 data were from spirometer machines at the Sheffield Adult cystic fibrosis (CF) centre, which were calculated with Knudson 
equation17 in whole numbers. Some %FEV
1
 data were from spirometer machines at the Pulmonary Function Unit which operationalised the Knudson equation 
differently; by calculating age to one decimal place to determine the predicted FEV
1
. These spirometer machines also provided %FEV
1
 to two decimal places, 
but this was rounded to whole numbers for the purpose of analysis. These results were presented at the 2017 North American CF Conference and were 
published as an abstract in Pediatric Pulmonology12.
‡ FEV
1
 volumes were available in litres to two decimal places from spirometer machines. Height data were also extracted to allow the calculation of predicted 
FEV
1
. This led us to uncover the inconsistency recording of height, which affected 30–40% of the study subjects and would have introduced erroneous 
variability to the %FEV
1
 because all equations for predicted %FEV
1
 are dependent on height. Height data were cleaned to weed out error. Where there was 
uncertainty regarding the height, the higher value was used to obtain a conservative estimate of %FEV
1
. To replicate calculation process of the spirometer 
machines at the Sheffield Adult CF centre, age was rounded down to a whole number and predicted FEV
1
 in volume were calculated to two decimal places 
using Knudson equation17. This was used to derive the %FEV
1
, which was then rounded to whole numbers for the purpose of analysis.Ԅ FEV
1
 and height data were extracted as above. %FEV
1




 calculated using the GLI equation18 as described above, then adjusted for baseline %FEV
1
 as described in the ‘Methods’ section. An adjusted %FEV
1
 
change of >0 meant the subject’s year-to-year fall in %FEV
1
 was less than expected for his / her baseline %FEV
1
, indicating better health outcomes.
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Table 3. Discrepancies in year-to-year %FEV
1
 variation with different methods of processing forced expiratory volume in 
one second (FEV
1
) data among adults aged ≥18 years.
Methods of processing FEV1 data:
Change in %FEV1, median (IQR)
Friedman 
test 
p-values2013 to 2014 
(n = 147)
2014 to 2015 
(n = 157)




 (calculated with Knudson equation) 
extracted from spirometer machines used for analysis
–2.0 (–6.0 to 1.0) –1.0 (–3.0 to 2.0) 0.0 (–3.0 to 2.0) 0.016
(2) FEV
1
 volume (in L) extracted and height data 
were cleaned, then %FEV
1
 calculated using Knudson 
equation
–2.0 (–5.0 to 1.0) –1.0 (–4.0 to 1.0) 0.0 (–3.8 to 2.0) 0.029
(3) FEV
1
 volume (in L) extracted and height data were 
cleaned, then %FEV
1
 calculated using GLI equation
–1.3 (–4.6 to 1.3) –1.0 (–3.2 to 1.4) –0.3 (–2.9 to 1.8) 0.090
(4) FEV
1
 volume (in L) extracted and height data were 
cleaned, then %FEV
1
 calculated using GLI equation, 
then change %FEV
1




0.5 (–2.4 to 3.3) 1.0 (–1.4 to 3.4) 1.6 (–1.3 to 3.7) 0.149
GLI equation altered the magnitude of year-to-year variation in 
%FEV
1
 although the trend of reduced year-to-year fall in %FEV
1
 
persisted (p=0.135). Adjustment for baseline %FEV
1
 further 
increased the p-value (p=0.210).
Similar results were obtained when restricting the analyses 
to those aged ≥18 years (see Table 3). Bland-Altman analyses 
comparing year-to-year variation in %FEV1 calculated from clean 
FEV1 data using Knudson equation
17 vs year-to-year variation in 
%FEV1 calculated from clean FEV1 data using GLI equation
18 
indicate the tendency for Knudson equation17 to over-estimate 
the magnitude of year-to-year fall in %FEV1 by a mean 
difference of 0.1–0.4% (see Figure 1).






We demonstrated that different centre-level year-to-year vari-
ation in %FEV
1
 results were obtained using different FEV
1
 data 
processing methods. In particular, year-to-year fall in %FEV
1
 was 
smaller in magnitude when %FEV
1
 was calculated using GLI 
equation18 instead of Knudson equation17. This is in part due 
to the demographic of our centre which has a relatively young 
adult population. A previous study found a near-linear %FEV
1
 
decline from childhood to adulthood with GLI equation, 
whereas there was accelerated %FEV
1
 decline during adoles-
cence and young adulthood when %FEV
1
 was calculated with 
Knudson equation24. One advantage of using the GLI equa-
tion, which is seamless across all ages, is that it improves the 
interpretation of %FEV
1
 decline24,25. Another advantage is 
that %FEV
1
 decline can be adjusted for baseline %FEV
1
 using 
ESCF reference values (since the ESCF values for %FEV
1
 
decline were calculated using the GLI equation20).
The limitation for all single-centre analysis is the potential lack 
of generalisability. Another limitation of our analysis is that the 
ESCF reference values used to adjust year-to-year variation in 
%FEV
1
 were derived using a cohort from around 15 years ago20, 
and may not represent the current population. Our results none-
theless highlighted that year-to-year variation in %FEV
1
 can 
be extremely sensitive to the FEV
1
 data processing methods. 
This is one of the challenges of using year-to-year variation in 
%FEV
1
 to infer quality of care. Another challenge is that %FEV
1
 
lacks sensitivity as an outcome measure. A recent sample size 
estimation using the UK CF registry data suggests that 273 adults 
per centre are needed to detect a 5% FEV
1
 difference at the 95% 
significance level26. The sensitivity of measures used to detect 
variations in care quality is particularly pertinent to CF because a 
relatively small population is spread across many centres. Indeed, 
only 6/28 (21.4%) of all UK adult CF centres have ≥273 adults. 
That means process measures, e.g. medication adherence, is 
important to detect variations in quality of CF care. Mant & 
Hicks previous demonstrated that measuring processes of care 
proven in randomised controlled trials to reduce death allows 
detection of meaningful differences in care quality for 
myocardial infarction with just 75 cases, whereas 8179 cases 
would be needed if mortality was used as the quality indicator27.
Given the limitations of FEV
1
 as an outcome measure in CF, 
results of centre comparisons based on FEV
1
 data should be 
carefully interpreted. Observational studies with year-to-year 
variation in %FEV
1
 as an outcome measure should carefully 
consider and clearly specify the data processing methods 
used.
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